The TNM-UICC classification is recommended for non-metastatic colon cancer. Factors such as number of lymph nodes examined and invaded, tumor stage, and molecular markers like MSI are important for prognosis and treatment decisions. MSI testing is recommended for stage II-III colon cancer to assess prognosis and identify Lynch syndrome.